Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Wassim AbidaDavid CampbellAkash PatnaikJeremy D ShapiroBrieuc SautoisNicholas J VogelzangEric G VoogAlan H BryceRay McDermottFrancesco RicciJulie RoweJingsong ZhangJosep Maria PiulatsKarim FizaziAxel S MerseburgerCelestia S HiganoLaurence E KriegerCharles J RyanFelix Y FengAndrew D SimmonsAndrea LoehrDarrin DespainMelanie DowsonFoad GreenSimon P WatkinsTony GolsorkhiSimon ChowdhuryPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
In this prospective, genomics-driven study of rucaparib in mCRPC, we found limited radiographic/PSA responses to PARP inhibition in men with alterations in ATM, CDK12, or CHEK2. However, patients with alterations in other DDR-associated genes (e.g., PALB2) may benefit from PARP inhibition.See related commentary by Sokolova et al., p. 2439.